Literature DB >> 9669285

ret rearrangements in Japanese pediatric and adult papillary thyroid cancers.

T Motomura1, Y E Nikiforov, H Namba, K Ashizawa, S Nagataki, S Yamashita, J A Fagin.   

Abstract

Oncogenic rearrangements of the ret proto-oncogene (ret/PTC) are found uniquely in papillary thyroid carcinomas. The prevalence of ret/PTC in these tumors varies widely, from 0% to 87%, among patient series from different geographical regions. The differences in the prevalence of ret rearrangement have been ascribed to age, genetic, and/or environmental factors. The very high prevalence of ret/PTC in tumors arising in children after the Chernobyl nuclear accident has generated speculation that this oncogene may be an indicator of overt or inadvertent radiation exposure. In Japan, the prevalence of ret activation is reportedly quite low (0% to 9%). Here we examined the frequency of ret rearrangements in papillary carcinomas from Japanese adults and children by means of reverse transcription polymerase chain reaction (RT-PCR) followed by Southern hybridization. Ret rearrangements were detected in 4 of 11 (36%) tumors from the adult population, and in 3 of 10 (30%) pediatric tumors. One child with a solid variant papillary carcinoma had a ret-PTC3 rearrangement, further supporting the association between the solid variant histotype and this particular rearrangement of ret. The present data do not support a major geographic difference in the prevalence of ret/PTC rearrangements in papillary carcinomas between Japan, the United States, and Italy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9669285     DOI: 10.1089/thy.1998.8.485

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  13 in total

Review 1.  Understanding the genotype of follicular thyroid tumors.

Authors:  Jennifer Hunt
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

2.  Prevalence of RET/PTC1 and RET/PTC3 gene rearrangements in Chennai population and its correlation with clinical parameters.

Authors:  P Jagan Mohan Rao; N V Vardhini; M V S Parvathi; P Balakrishna Murthy; G Sudhakar
Journal:  Tumour Biol       Date:  2014-06-24

Review 3.  RET proto-oncogene mutations in thyroid carcinomas: clinical relevance.

Authors:  F Pacini; R Elisei; C Romei; A Pinchera
Journal:  J Endocrinol Invest       Date:  2000-05       Impact factor: 4.256

4.  RET/PTC and CK19 expression in papillary thyroid carcinoma and its clinicopathologic correlation.

Authors:  Eunah Shin; Woung Youn Chung; Woo Ick Yang; Cheong Soo Park; Soon Won Hong
Journal:  J Korean Med Sci       Date:  2005-02       Impact factor: 2.153

Review 5.  RET/PTC rearrangement in thyroid tumors.

Authors:  Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

6.  RET/PTC fusion gene rearrangements in Japanese thyroid carcinomas.

Authors:  Ken-ichi Nibu; Naoki Otsuki; Kazunari Nakao; Masashi Sugasawa; Jay L Rothstein
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-09-11       Impact factor: 2.503

7.  Thyroid carcinoma in children and adolescents-systematic review of the literature.

Authors:  Fernanda Vaisman; Rossana Corbo; Mario Vaisman
Journal:  J Thyroid Res       Date:  2011-09-04

Review 8.  Mutation Profile of Well-Differentiated Thyroid Cancer in Asians.

Authors:  Young Shin Song; Jung Ah Lim; Young Joo Park
Journal:  Endocrinol Metab (Seoul)       Date:  2015-09

9.  DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells.

Authors:  M Gandhi; L W Dillon; S Pramanik; Y E Nikiforov; Y-H Wang
Journal:  Oncogene       Date:  2010-01-25       Impact factor: 9.867

10.  BRAF(V600E) mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima: a different oncogenic profile from Chernobyl.

Authors:  Norisato Mitsutake; Toshihiko Fukushima; Michiko Matsuse; Tatiana Rogounovitch; Vladimir Saenko; Shinya Uchino; Masahiro Ito; Keiji Suzuki; Shinichi Suzuki; Shunichi Yamashita
Journal:  Sci Rep       Date:  2015-11-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.